Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 0.3% in the third quarter, HoldingsChannel reports. The fund owned 1,374,697 shares of the company’s stock after buying an additional 3,528 shares during the period. Geode Capital Management LLC’s holdings in Protagonist Therapeutics were worth $61,873,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of PTGX. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock worth $95,000 after purchasing an additional 379 shares during the period. GAMMA Investing LLC lifted its stake in shares of Protagonist Therapeutics by 749.2% in the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after acquiring an additional 487 shares during the period. Exchange Traded Concepts LLC bought a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $43,000. CWM LLC increased its stake in shares of Protagonist Therapeutics by 910.3% during the third quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after acquiring an additional 1,147 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Protagonist Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 115,765 shares of the company’s stock worth $5,209,000 after purchasing an additional 1,359 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Insider Activity

In other news, insider Suneel Gupta sold 103,437 shares of Protagonist Therapeutics stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the transaction, the insider now owns 256,174 shares in the company, valued at approximately $11,794,250.96. The trade was a 28.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $46.96, for a total value of $3,687,299.20. Following the completion of the sale, the chief executive officer now directly owns 435,208 shares of the company’s stock, valued at approximately $20,437,367.68. This represents a 15.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 209,863 shares of company stock worth $9,689,847 over the last 90 days. 5.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. The Goldman Sachs Group assumed coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set a “neutral” rating and a $47.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, December 10th. TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Finally, Wedbush reiterated an “outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $53.78.

Protagonist Therapeutics Trading Up 4.9 %

PTGX stock opened at $41.49 on Friday. Protagonist Therapeutics, Inc. has a one year low of $20.88 and a one year high of $48.89. The firm has a 50-day moving average of $44.02 and a two-hundred day moving average of $40.96. The firm has a market capitalization of $2.47 billion, a PE ratio of 15.60 and a beta of 2.18.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.